abacavir

Abacavir or tenofovir for first-line?

Graham Stocks — Wed, 23 Nov 2011 21:10:02 -0800

According to the Canadian Observational CohortIn epidemiology, a group of individuals with some characteristics in common. A cohort study is a special kind of clinical trial which looks at a treatment or treatment strategy in a cohort of people. collaboration, abacavir (ABC) or tenofovir (TDF) are equally effective in first-line treatment.

The authors found that in their group of treatment-naive patients starting treatment, there was no difference in time to suppression with ABC/3TC (Kivexa) versus TDF/FTC (Truvada).

Tenofovir vs abacavir: the saga continues

Graham Stocks — Wed, 31 Aug 2011 23:16:26 -0700

Compared to abacavir, tenofovir does increase bone mineral density (BMD) loss but not fracture risk, according to the results from the STEAL trial reported at the IAS Conference in Rome.

Drugs linked to heart risks, minimal

Graham Stocks — Wed, 25 May 2011 23:36:20 -0700

A Canadian study has associated abacavir, efavirenz, lopinavir and ritonavir with an increased risk of heart attackA life-threatening emergency in which the blood supply to the heart is suddenly cut off, causing the heart muscle (myocardium) to die from lack of oxygen.. The research also showed that patients with HIV had twice the risk of heart attack compared to matched HIV
negative controls.

Snippets from ASHM

Graham Stocks — Wed, 01 Dec 2010 17:34:41 -0800

The Australasian HIV/AIDS Conference was held in Sydney in October. Here are some of the treatment highlights:

Treatments news from the IAS Conference

Wed, 19 Aug 2009 18:52:42 -0700

A roundup of HIV treatments developments from the IAS Conference in Cape Town.

Other common tests

Graham Stocks — Thu, 06 Aug 2009 17:08:34 -0700

Viral loadA measurement of the quantity of HIV RNA in the blood. Viral load blood test results are expressed as the number of copies (of HIV) per milliliter of blood plasma. and CD4 cell count results are two of the main tests used to inform treatment decisions about starting or changing treatments. Usually every time you have regular blood tests a whole range of other tests are done. Some of these are useful in monitoring for possible drug side effects and potential organ damage.

HAART on the heart

Jill Sergeant — Thu, 04 Jun 2009 23:20:40 -0700

Starting Highly Active AntiretroviralA medication or other substance which is active against retroviruses such as HIV. Therapy can improve some of the things that lead to heart problems but not all of them, a recent study has revealed. Arteries which are already thickened or hardened do not improve on treatment. Metabolic complications, including increases in blood levels of lipids, are common in people on treatment and can also contribute to this condition.

ASHM 2008: Treatment side effects

David Menadue — Mon, 24 Nov 2008 16:42:29 -0800

Abacavir should be avoided by people who are in the high cardiovascular risk group.

Abacavir and heart attacks

admin — Wed, 25 Jun 2008 17:59:36 -0700

Latest results presented by investigators at the CROI meeting in February in Boston suggested that treatment with abacavir (also found in the combination pills Kivexa and Trizivir) and ddI (didanosine, Videx) may significantly increase the risk of myocardial infarction, or heart attackA life-threatening emergency in which the blood supply to the heart is suddenly cut off, causing the heart muscle (myocardium) to die from lack of oxygen..

IAS 2007: Promising signs

Paul Kidd — Sun, 14 Oct 2007 07:10:00 -0700

A major HIV/AIDS medical conference in Sydney has generated lots of news on the treatments front, reports Paul Kidd.